Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04BOT
|
|||
| Former ID |
DNCL002604
|
|||
| Drug Name |
Dalotuzumab
|
|||
| Synonyms |
AC1MHYZY; SCHEMBL4534994; BDBM82422; NSC_3035240; CAS_109872-41-5; D06396; L000945; 4-amino-N-(1-azabicyclo[3.3.1]nonan-4-yl)-5-chloro-2-methoxybenzamide
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Company |
Merck
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01605396) A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.